Publisher
Springer Science and Business Media LLC
Subject
Anesthesiology and Pain Medicine,Clinical Neurology
Reference28 articles.
1. McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020;9:441–52. https://doi.org/10.1007/s40122-020-00189-x.
2. Burns C. Pregabalin and gabapentin to be reclassified as Class C controlled substances. The Pharmaceutical Journal. 2018. https://www.pharmaceutical-journal.com/news-and-analysis/news/pregabalin-and-gabapentin-to-be-reclassified-as-class-c-controlled-substances/20205611.article. Accessed 3 May 2020.
3. Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag Healthc Policy. 2018;11(1):109–16.
4. Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse—proactive pharmacovigilance. N Engl J Med. 2018;379:205–7.
5. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403–26.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献